PT  - JOURNAL ARTICLE
AU  - Ameenat Lola Solebo
AU  - Jugnoo S Rahi
AU  - Andrew D Dick
AU  - Athimalaipet V Ramanan
AU  - Jane Ashworth
AU  - Clive Edelsten
ED  - ,
TI  - Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK
AID  - 10.1136/bjophthalmol-2018-313789
DP  - 2020 Jan 01
TA  - British Journal of Ophthalmology
PG  - 11--16
VI  - 104
IP  - 1
4099  - http://bjo.bmj.com/content/104/1/11.short
4100  - http://bjo.bmj.com/content/104/1/11.full
SO  - Br J Ophthalmol2020 Jan 01; 104
AB  - Background/aims There is a paucity of high-level evidence to support the management of childhood uveitis, particularly for those children without juvenile idiopathic arthritis uveitis (JIA). We undertook a modified Delphi consensus exercise to identify agreement in the management of chronic anterior uveitis (CAU), the most common manifestation of childhood disease.Methods A four-round, two-panel process was undertaken between June and December 2017. Paediatric uveitis specialists identified through multiple sources, including a multicentre network (the Paediatric Ocular Inflammation Group), were invited to participate. They were asked whether they agreed with items derived from existing guidelines on the management of JIA-U when extrapolated to the population of all children with CAU. Consensus was defined as agreement greater than or equal to 75% of respondents.Results 26 of the 38 (68%) invited specialists participated with the exercise, and response rates were 100% for rounds one to three, and 92% for round four. Consensus was reached on 23 of the 44 items. Items for which consensus was not reached included management at presentation, use of systemic and periocular steroids for children with severe disease and the role of conventional steroid sparing immunosuppressants beyond methotrexate.Conclusion The areas of management uncertainty at the level of the group, as indicated by absence of consensus, reflect the areas where the evidence base is particularly poor. Our findings identify the key areas for the future research needed to ensure better outcomes for this blinding childhood ocular inflammatory disorders.